Reported Earlier, HUTCHMED Publishes Phase III Sovleplenib Results, 48.4% Response Rate In ITP Patients Versus 0% In Placebo Group
Reported Earlier, HUTCHMED Publishes Phase III Sovleplenib Results, 48.4% Response Rate In ITP Patients Versus 0% In Placebo Group
據早前報道，哈濱藥業公佈了Sovleplenib三期試驗結果，ITP患者響應率爲48.4%，安慰劑組爲0%。
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo —
該研究表明，與安慰劑組0%相比，治療顯示出48.4%的持久反應率。
— Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA1 exposure —
EHA的演示展示子組分析，無論之前接受的治療線數或之前的TPO / TPO-RA1暴露如何，都會產生一致的益處。
— Data supported regulatory submission in China accepted in January 2024 —
該數據支持2024年1月被中國政府審查部門批准的監管提交。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。